H2 2025 Whitepaper: China's GI Health Dietary Supplements & Probiotics Market Analysis

Key Finding 1

China's online GI health dietary supplements market reached CN¥ 3.88 billion in the first three quarters of 2025, accelerating +14.5% YoY as the sector shifts from reactive treatment toward proactive health management.

The broader online dietary supplements market exceeded CN¥ 87 billion in the January-September period, growing nearly +19% YoY across China's leading marketplaces and content-led commerce channels. Within this landscape, GI health represents a modest but steadily recovering segment at approximately 5% of total market value. Notably, the GI pharmaceutical market achieved +30% growth, confirming an expanding patient population that provides demand-side support for the supplements market. This "treatment plus wellness" dual-track dynamic signals that consumer spending patterns are moving beyond acute symptom relief toward sustained, preventive digestive health management.

Key Finding 2

Probiotics dominate the GI health market with CN¥ 2.6 billion in sales and over 60% penetration, but growth has slowed to +3.8% YoY, driving differentiation through strain customization and scenario-specific positioning.

The GI probiotics sub-segment alone is projected to surpass CN¥ 3.7 billion in 2025, growing +6.7% YoY after a post-peak correction in 2024. Market competition is intensifying as new entrants leverage Douyin-native strategies. Jiangzhong and Purmeo grew through precision livestream commerce and platform campaign participation. Meanwhile, food-medicine homology ingredients such as astragalus (+350.6% YoY), Chinese yam (+666.9% YoY), and digestive enzymes (+366.4% YoY) are emerging as high-growth alternatives, typically formulated in compound preparations with probiotics.

Key Finding 3

Consumer purchasing decisions center on efficacy (79%) and adverse reactions (17%), while scenario-based consumption for work, travel, and social occasions opens new portable probiotic product opportunities.

Social media analysis reveals that GI health concerns are shifting from a predominantly female demographic (72%) to broader all-age coverage, with the 36+ age group showing accelerating growth. The consumer demand landscape extends beyond traditional capsule and powder formats into snackified probiotics, with chewable tablets (+48% YoY), oral liquids (+45% YoY), and drops (+78% YoY) emerging as the fastest-growing delivery formats. Portable probiotic products addressing work and travel scenarios achieved CN¥ 13.6 million in sales with +67.6% YoY growth, representing an underserved niche with strong expansion potential.

Key Finding 4

GLP-1 probiotic delivery systems represent a potentially transformative technology convergence, with multiple companies developing oral probiotic-based GLP-1 secretion enhancement targeting the weight management market.

As GLP-1 drug demand surges, several biotech companies are developing probiotic-based oral delivery systems that bypass injectable administration. The Ningbo Menovo JH389 project demonstrated favorable clinical trial results, with obesity models showing 8.3g weight reduction versus control (P<0.001) and 28% insulin sensitivity improvement. Filed as dietary supplements to avoid lengthy pharmaceutical approval cycles, these products are expected to launch in 2026, positioning probiotics as a bridge between wellness supplements and pharmaceutical interventions.